| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10301 | Emodepside Featured | Emodepside (PF 1022-221) is a cyclooctadepsipeptide with broad-spectrum anthelmintic activity. |
|
| DC9762 | Emricasan Featured | Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor. |
|
| DC5902 | Emtricitabine Featured | Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve |
|
| DC8177 | Enclomiphene citrate Featured | Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. |
|
| DC8265 | Endoxifen Featured | Endoxifen is a Estrogen receptor α (ERα) ligand; potent antiestrogen,an active metabolite of the cancer drug tamoxifen. |
|
| DC6909 | Entinostat (MS-275) Featured | Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2. |
|
| DC8300 | Entrectinib (RXDX-101) Featured | Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions. |
|
| DC5057 | Enzastaurin (LY317615) Featured | Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3. |
|
| DCAPI1356 | Epalrestat Featured | Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. |
|
| DC11433 | Vatiquinone | EPI-743 (Vatiquinone,EPI-589) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone. |
|
| DC9260 | Eptapirone Featured | Eptapirone (F-11,440) is a very potent and highly selective 5-HT1A receptor full agonist of the azapirone family. |
|
| DC7927 | EPZ011989 Featured | EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
|
| DC11387 | Erdafitinib Featured | Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively. |
|
| DCAPI1539 | Eribulin Mesylate Featured | Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. |
|
| DCAPI1516 | Eribulin | Eribulin Mesylate (E7389 Mesylate), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. |
|
| DC2101 | Erlotinib free base Featured | Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
|
| DC3139 | Erlotinib hydrochloride Featured | Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
|
| DC8182 | Bempedoic Acid(ETC-1002;ESP-55016) Featured | ETC-1002(ESP-55016) is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule; activator of hepatic AMP-activated protein kinase (AMPK); also has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM). |
|
| DC8489 | ETC-159 Featured | ETC-159 is a potent and specific inhibitor of Wnt secretion. ETC-159 inhibits _beta_-catenin reporter activity in a dose-dependent manner with an IC50 of 2.9 nM. |
|
| DCAPI1535 | Etodolac | Etodolac is a Cox-2 inhibitor with anti-inflammatory and analgesic activity. Etodolac is shown to inhibit growth and PCNA expression and induce cell cycle arrest in human hepatocellular carcinoma cell lines, in addition to suppressing the occurrence of ab |
|
| DC10040 | Etrasimod(APD334) Featured | Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1(S1P1) receptor with an IC50 value of 1.88 nM in CHO cells. |
|
| DC4234 | Etravirine | Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). |
|
| DC7125 | Evacetrapib (LY2484595) Featured | Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. |
|
| DC1501 | Everolimus Featured | Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM. |
|
| DC10380 | Evobrutinib Featured | Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174. |
|
| DC8342 | EW-7197 Featured | EW-7197 is a potent ALK5 inhibitor. EW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy. |
|
| DCAPI1084 | Ezetimibe (Zetia) Featured | Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. |
|
| DC9821 | Ezutromid Featured | Ezutromid is a novel Small utrophin's translation modulator with EC50 of 0.4 uM . |
|
| DC11329 | Fadrozole (hydrochloride) Featured | Fadrozole is a non-steroidal aromatase inhibitor (IC50s = 5 and 1.4 nM for human placental and rat ovarian microsomal aromatase, respectively). |
|
| DCAPI1011 | Famciclovir (Famvir) | Famciclovir (Famvir) |
|
